RESPIVERT
Respivert is a small molecule drug discovery company for the treatment of chronic obstructive pulmonary diseases, asthma, and cystic fibrosis. The company was incorporated in 2006 and is based in High Wycombe, United Kingdom.
RESPIVERT
Social Links:
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2006-01-01
Address:
High Wycombe, Buckinghamshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.respivert.com
Total Employee:
11+
Status:
Closed
Contact:
44 20 7594 1215
Total Funding:
0
Technology used in webpage:
Google Maps API Network Solutions DNS Symantec.cloud
Similar Organizations
Merck
Merck is a biopharmaceutical company that offers medicines and vaccines for various diseases.
Investors List
Eight Roads Ventures
Eight Roads Ventures investment in Venture Round - RespiVert
Official Site Inspections
http://www.respivert.com
- Host name: 208.91.197.132
- IP address: 208.91.197.132
- Location: British Virgin Islands
- Latitude: 18.5
- Longitude: -64.5
- Timezone: America/Tortola
More informations about "RespiVert"
RespiVert - Crunchbase Company Profile & Funding
Respivert is a small molecule drug discovery company for the treatment of chronic obstructive pulmonary diseases, asthma, and cystic fibrosis. The company was incorporated in 2006 and …See details»
RespiVert Company Profile 2024: Valuation, Investors ... - PitchBook
Information on acquisition, funding, cap tables, investors, and executives for RespiVert. Use the PitchBook Platform to explore the full profile.See details»
RespiVert - VentureRadar
RespiVert is a small molecule drug discovery company working towards the identification of new treatments for patients with Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis …See details»
Respivert | Advent Life Sciences
Respivert developed a pipeline of novel, narrow spectrum, kinase inhibitors, that possessed a unique anti-inflammatory profile, and which were being developed as first-in-class treatments for moderate to severe asthma, COPD and cystic …See details»
RespiVert - Funding, Financials, Valuation & Investors - Crunchbase
Respivert is a small molecule drug discovery company for the treatment of chronic obstructive pulmonary diseases.See details»
Centocor Ortho Biotech Inc. Acquires RespiVert Ltd., Strengthens ...
HORSHAM, Pa., June 1 /PRNewswire/ -- Centocor Ortho Biotech Inc. today announced that it has acquired RespiVert Ltd., a privately held drug discovery company focused on developing small …See details»
Centocor Ortho Biotech acquires RespiVert - Crunchbase
RespiVert Respivert is a small molecule drug discovery company for the treatment of chronic obstructive pulmonary diseases. Acquiring Organization: Centocor Ortho BiotechSee details»
Centocor Ortho Biotech Inc. Acquires RespiVert Ltd., Strengthens ...
HORSHAM, Pa., June 1 /PRNewswire/ -- Centocor Ortho Biotech Inc. today announced that it has acquired RespiVert Ltd., a privately held drug discovery company focused on developing...See details»
J&J buys UK biotech RespiVert - PharmaTimes
Jun 1, 2010 · Johnson & Johnson has acquired the UK’s RespiVert, a privately-held drug discovery company focused on developing inhaled therapies for pulmonary diseases. J&J’s …See details»
J&J's Centocor buys RespiVert - Fierce Biotech
Jun 1, 2010 · Centocor Ortho Biotech, a division of Johnson & Johnson (NYSE: JNJ), announced today that it has acquired acquired RespiVert, a private company that's developing small …See details»
Centocor Snaps Up Inhaled Respiratory Therapeutics …
Jun 1, 2010 · Young company aims to develop products that address resistance of lung diseases to inhaled corticosteroids. Centocor Ortho Biotech has gained a pipeline of early-stage inhaled treatments for lung...See details»
Press Releases - Pulmatrix
Jun 13, 2017 · (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it …See details»
COPD Therapy Licensing Agreement Signed by Pulmatrix and …
Jun 15, 2017 · ISPERSE can work with virtually any drug class — from small molecules to biologics — including RespiVert’s kinase inhibitors, according to Pulmatrix. The agreement …See details»
New tech transfer models gain traction with deal flow
One view of the acquisition in June of respiratory drug discovery company Respivert by Centocor Ortho Biotech of Horsham, Pennsylvania, is that it is just another commonplace example of an...See details»
RV-1729 - Drug Targets, Indications, Patents - Synapse
RV1729 is a new medicine being developed for the potential treatment of asthma and smoking related lung disease (also known as chronic obstructive pulmonary disease - COPD). The …See details»
RV-6153 - Drug Targets, Indications, Patents - Synapse - Patsnap
RV-6153: a PI3Kγ inhibitors, PI3Kδ inhibitors Drug, Initially developed by RespiVert Ltd., Now, its global highest R&D status is Discontinued, Mechanism: PI3Kγ inhibitors(Phosphatidylinositol 3 …See details»
RV-568 - Drug Targets, Indications, Patents - Synapse
RV568 is being developed as a possible treatment of smoking related lung disease (also known as Chronic Obstructive Pulmonary Disease - COPD). The main purpose of this study is to …See details»
Research programme: lung disorder therapies - RespiVert
If your organization has a subscription, there are several access options, even while working remotely: Working within your organization’s network Login with username/password or try to …See details»
RV 6153 - AdisInsight - Springer
Aug 28, 2019 · Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases. RespiVert, a subsidiary of Janssen Biotech, is developing RV …See details»
RV 568 - AdisInsight - Springer
If your organization has a subscription, there are several access options, even while working remotely: Working within your organization’s network Login with username/password or try to …See details»